A major breakthrough in Shanghai blood research, another type of leukemia is expected to be overcome.

, Shanghai Jiaotong University School of Medicine affiliated RuijinHospital
Shanghai Institute of Hematology yesterday (27) disclosed that M2 leukemia research is expected to achieve a major breakthrough, the project has now completed pre-clinical trials and entered the drug development stage, another type of leukemia is expected to be overcomeShanghai Institute of Hematology now includes Ruijin, Renji, Xinhua, City nine,Children'sMedical Center, City I,Children'sHospitalhematology and Shanghai Jiaotong University School of Medicine, a total of 9 member units, is a close combination of academic researchThe Institute currently has one academician of chinese Academy of Sciences, two academicians of the Academy of Engineering and seven recipients of the National Science Fund for Distinguished Young PeopleAfter two decades of unremitting exploration and progress, Shanghai Institute of Hematology, as the pioneer of the internationaltumorinduced differentiation and apoptosis target treatment, took the lead in the basic research and clinical treatment of acute early granulocytic leukemia (APL), and applied all-trans-aritic acid and arsenic trioxide for collaborative treatment, making the five-year disease-free survival rate of china's acute early granule leukemia reach more than 90%, and become the first basic cure of myelin leukemia in human historyAt present, the latest research results of Shanghai Blood Research Institute have been expected to further expand the induced differentiation treatment of leukemia to the second type of leukemia - M2 leukemiaThe researchers have found that the Chinese medicine extract, dongling meth, may have achieved good results for M2 leukemia through targeted treatment, and has made important progress in basic theory and animal trialsYesterday, Shanghai Hematology Research Institute and Jiangsu Hengrui Pharmaceutical Co., Ltdsigned a cooperation agreement on clinical trials of the treatment of M2 leukemia, marking a critical and important step in the transformation of basic research results in this field into clinical treatment